サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790217

米国の動物用抗感染症薬市場規模、シェア、動向分析レポート：動物別、製品別、投与経路別、タイプ別、流通チャネル別、セグメント別予測、2025年～2033年

U.S. Veterinary Anti-infectives Market Size, Share & Trends Analysis Report By Animal, By Product, By Route Of Administration, By Type, By Distribution Channel, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
米国の動物用抗感染症薬市場規模、シェア、動向分析レポート：動物別、製品別、投与経路別、タイプ別、流通チャネル別、セグメント別予測、2025年～2033年
出版日: 2025年07月02日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の動物用抗感染症薬市場の概要

米国の動物用抗感染症薬市場は、2024年に22億3,000万米ドルと推定され、2033年には35億5,000万米ドルに達すると予測され、2025～2033年のCAGRは5.4%で成長すると予測されます。市場を牽引すると予想される主要因には、動物感染症の増加、研究開発イニシアチブの増加、慎重な抗生物質使用の後押し、新規治療法の開発、人工知能（AI）の応用拡大などがあります。

米国の動物用抗感染症薬市場は、コンパニオンアニマルや家畜の抗菌薬耐性（AMR）に対する懸念の高まりによって、大きな変革期を迎えています。2025年1月にNews-Medical誌で取り上げられた研究では、家庭犬がいかに抗生物質耐性のサルモネラ菌を保有して感染させ、人獣共通感染症のリスクを高めているかが強調されています。このため獣医師や飼い主の間で意識が高まり、コンパニオンアニマルのセグメントではより的を絞ったより安全な抗感染症ソリューションへの需要が高まっています。獣医療現場は、広域スペクトル抗生物質の無差別使用に対してますます慎重になっており、狭スペクトル薬剤、耐性緩和療法、さらにはプロバイオティクスのような予防医療オプションへの関心を促しています。この動向はまた、動物用診断薬、特に責任を持って治療方針を決定するのに役立つ感受性検査の成長にも拍車をかけています。

抗生物質への依存を減らすための技術革新が、畜産部門の市場をさらに形成しています。2024年12月のペンシルベニア州立大学の研究では、抗生物質の代わりにバクテリオファージを用いた乳牛の乳房炎に対する有望な新しい治療法が明らかになりました。この画期的な研究は、ファージ療法、免疫調整剤、ペプチド、その他の生物製剤を含む抗生物質代替療法の市場拡大を浮き彫りにしています。FDAとUSDA別、食用動物への日常的な抗生物質使用を抑制するための規制圧力は、特に酪農業従事者や牛肉生産者の間で、このような代替抗生物質の採用を増加させています。これらの利害関係者は現在、牛群の健康と生産性を維持しつつ、抗菌薬スチュワードシップ・ガイドラインに準拠した効果的な治療法を求めており、その結果、従来型抗生物質だけでなく、動物用抗感染症の展望が広がっています。

一方、米国獣医師会（AVMA）は、責任ある抗生物質の使用をめぐる獣医師と飼い主のコミュニケーションの重要性を強調しています。このスチュワードシップ主導のアプローチは、米国の獣医療現場全体の配合行動を再構築しつつあります。獣医師が診断に基づいた治療を優先し、経験的な抗生物質の使用を減らすにつれて、診断、感受性検査、より洗練された抗感染療法への需要が高まっています。製薬会社は、スチュワードシップの原則に沿った精密医薬品や教育リソースを開発することで対応しています。このシフトは、より良い健康アウトカムを保証し、動物用抗感染症薬のイノベーションに対する市場の持続的な需要を促進します。

概要：米国市場は、ペットにおけるAMRの脅威の検出、家畜の病気に対する非抗生物質治療の出現、獣医スチュワードシップ文化の高まりという3つの大きな力によって推進されています。これらの要因によって、市場各社は製品ポートフォリオの多様化、より安全な代替薬の研究開発への投資、責任ある抗生物質使用を支援するツールの開発を進めています。その結果、抗菌剤耐性との闘いにおいて、市場は精密さ、持続可能性、革新性へと急速に進化しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の動物用抗感染症薬市場の変動動向と展望

  • 市場系統の展望
    • 親市場
    • 補助市場
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • 米国の動物用抗感染症薬市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析
    • 主要国による規制枠組み
    • 主要国別、主要種による動物推定個体数（2021～2023年）
    • 主要感染症の有病率（主要種別）（2024年）
    • COVID-19の影響分析

第4章 米国の動物用抗感染症薬市場：動物別、推定・動向分析

  • セグメントダッシュボード
  • 米国の動物用抗感染症薬市場：動物変動分析
  • 米国の動物用抗感染症薬市場規模と動向分析（動物別、2021～2033年）
  • 家畜
    • 家禽
    • 豚
    • 牛
    • 羊とヤギ
    • 魚
    • その他
  • コンパニオンアニマル
    • 犬
    • 猫
    • その他

第5章 米国の動物用抗感染症薬市場：製品別、推定・動向分析

  • セグメントダッシュボード
  • 米国の動物用抗感染症薬市場：製品変動分析
  • 米国の動物用抗感染症薬市場規模と動向分析（製品別、2021～2033年）
  • 抗菌剤
    • セファロスポリン
    • テトラサイクリン
    • ペニシリン
    • マクロライド
    • その他（キノール、スルホンアミド、ポリミキシン）
  • 抗真菌薬
  • 抗ウイルス薬
  • その他

第6章 米国の動物用抗感染症薬市場：投与経路別、推定・動向分析

  • セグメントダッシュボード
  • 米国の動物用抗感染症薬市場：投与経路変動分析
  • 米国の動物用抗感染症薬市場規模と動向分析（投与経路別、2021～2033年）
    • 経口
    • 注射
    • その他

第7章 米国の動物用抗感染症薬市場：タイプ別、推定・動向分析

  • セグメントダッシュボード
  • 米国の動物用抗感染症薬市場：タイプ別変動分析
  • 米国の動物用抗感染症薬市場規模と動向分析（タイプ別、2021～2033年）
    • 市販薬
    • 処方箋

第8章 動物用抗感染症薬市場：流通チャネル別、推定・動向分析

  • セグメントダッシュボード
  • 米国の動物用抗感染症薬市場：流通チャネル変動分析
  • 米国の動物用抗感染症薬市場規模と動向分析（流通チャネル別、2021～2033年）
    • 病院/クリニック薬局
    • 小売薬局
    • eコマース

第9章 競合情勢

  • 市場参入企業の分類
  • 企業の市況分析/ヒープマップ分析
  • 企業プロファイル
    • Zoetis
    • Boehringer Ingelheim
    • Merck & Co. Inc.
    • Dechra Pharmaceuticals Plc.
    • Elanco Animal Health
    • Ceva Sante Animale
    • Virbac
    • Biogenesis Bago
    • Vetoquinol
    • Calier
    • Norbrook Laboratories
  • 戦略マッピング
    • 合併と買収
    • パートナーシップとコラボレーション
    • 拡大
    • 製品発売
    • 製品承認
    • その他
  • 主要企業一覧
    • メーカー一覧
    • 販売代理店一覧
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Veterinary Anti-infectives Market, By Animal, 2021 - 2033 (USD Million)
  • Table 4 U.S. Veterinary Anti-infectives Market, By Livestock, 2021 - 2033 (USD Million)
  • Table 5 U.S. Veterinary Anti-infectives Market, By Companion Animal, 2021 - 2033 (USD Million)
  • Table 6 U.S. Veterinary Anti-infectives Market, By Product, 2021 - 2033 (USD Million)
  • Table 7 U.S. Veterinary Anti-infectives Market, By Antimicrobial, 2021 - 2033 (USD Million)
  • Table 8 U.S. Veterinary Anti-infectives Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 9 U.S. Veterinary Anti-infectives Market, By Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Veterinary Anti-infectives Market, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Veterinary Anti-infectives Market, Market Segmentation
  • Fig. 8 Market Driver Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 U.S. Veterinary Anti-infectives Market, for Animal, 2021 - 2033 (USD Million)
  • Fig. 15 U.S. Veterinary Anti-infectives Market, for Livestock Animal, 2021 - 2033 (USD Million)
  • Fig. 16 U.S. Veterinary Anti-infectives Market, for Poultry, 2021 - 2033 (USD Million)
  • Fig. 17 U.S. Veterinary Anti-infectives Market, for Swine, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. Veterinary Anti-infectives Market, for Cattle, 2021 - 2033 (USD Million)
  • Fig. 19 U.S. Veterinary Anti-infectives Market, for Sheep & Goats, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. Veterinary Anti-infectives Market, for Fish, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Veterinary Anti-infectives Market, for Companion Animal, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. Veterinary Anti-infectives Market, for Dogs, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Veterinary Anti-infectives Market, for Cats, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Veterinary Anti-infectives Market, for Product, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Veterinary Anti-infectives Market, for Antimicrobial, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Veterinary Anti-infectives Market, for Tetracyclines, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. Veterinary Anti-infectives Market, for Penicillin, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Veterinary Anti-infectives Market, for Cephalosporins, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. Veterinary Anti-infectives Market, for Macrolides, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Veterinary Anti-infectives Market, for Quinolones, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Veterinary Anti-infectives Market, for Antifungals, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Veterinary Anti-infectives Market, for Antivirals, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. Veterinary Anti-infectives Market, for Antiparasitic, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. Veterinary Anti-infectives Market, for Route of Administration, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Veterinary Anti-infectives Market, for Oral, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. Veterinary Anti-infectives Market, for Injectable, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Veterinary Anti-infectives Market, for Topical, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. Veterinary Anti-infectives Market, for Type, 2021 - 2033 (USD Million)
  • Fig. 43 U.S. Veterinary Anti-infectives Market, for OTC, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. Veterinary Anti-infectives Market, for Prescription, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. Veterinary Anti-infectives Market, for Distribution Channel, 2021 - 2033 (USD Million)
  • Fig. 46 U.S. Veterinary Anti-infectives Market, for Hospital/ Clinic Pharmacy, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Veterinary Anti-infectives Market, for Retail Pharmacies, 2021 - 2033 (USD Million)
目次
Product Code: GVR-4-68040-656-7

U.S. Veterinary Anti-infectives Market Summary

The U.S. veterinary anti-infectives market was estimated at USD 2.23 billion in 2024 and is projected to reach USD 3.55 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, increasing R&D initiatives, a boost to prudent antibiotic use, development of novel treatments, and growing applications of Artificial Intelligence (AI).

The veterinary anti-infectives market in the U.S. is undergoing a significant transformation, driven by rising concerns over antimicrobial resistance (AMR) in companion animals and livestock. A January 2025 study highlighted in News-Medical underscores how household dogs can harbor and transmit antibiotic-resistant Salmonella, elevating the risk of zoonotic infections. This has raised awareness among veterinarians and pet owners, leading to a growing demand for more targeted and safer anti-infective solutions in the companion animal segment. Veterinary practices are increasingly cautious about the indiscriminate use of broad-spectrum antibiotics, prompting interest in narrow-spectrum drugs, resistance-mitigating therapies, and even preventive care options like probiotics. This trend also fuels the growth of veterinary diagnostics, especially for susceptibility testing that helps guide treatment decisions responsibly.

Innovations to reduce antibiotic reliance further shape the market in the livestock sector. A Penn State study from December 2024 revealed a promising new treatment for mastitis in dairy cows using bacteriophages instead of antibiotics. This breakthrough highlights the expanding market for antibiotic alternatives, including phage therapies, immunomodulators, peptides, and other biologics. Regulatory pressure from the FDA and USDA to curb routine antibiotic use in food-producing animals has increased the adoption of such alternatives, especially among dairy and beef producers. These stakeholders are now seeking effective treatments that comply with antimicrobial stewardship guidelines while maintaining herd health and productivity, thus broadening the veterinary anti-infectives landscape beyond conventional antibiotics.

Meanwhile, the American Veterinary Medical Association (AVMA) has emphasized the importance of communication between veterinarians and animal owners around responsible antibiotic use. This stewardship-led approach is reshaping prescribing behavior across U.S. veterinary practices. As veterinarians prioritize diagnosis-driven treatments and reduce empirical antibiotic use, there is an increasing demand for diagnostics, sensitivity testing, and more refined anti-infective therapies. Pharmaceutical companies are responding by developing precision drugs and educational resources that align with stewardship principles. This shift ensures better health outcomes and drives sustained market demand for innovation in veterinary anti-infectives.

In summary, the U.S. market is propelled by three major forces: the detection of AMR threats in pets, the emergence of non-antibiotic treatments for livestock diseases, and a growing culture of veterinary stewardship. These factors drive market players to diversify product portfolios, invest in R&D for safer alternatives, and develop tools supporting responsible antibiotic use. The result is a market rapidly evolving toward precision, sustainability, and innovation in the fight against antimicrobial resistance.

U.S. Veterinary Anti-infectives Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary anti-infectives market report based on animal, product, route of administration, type, and distribution channel.

  • Animal Outlook (Revenue, USD Million, 2021 - 2033)
  • Livestock Animal
    • Poultry
    • Swine
    • Cattle
    • Sheep & Goats
    • Fish
    • Others
  • Companion Animal
    • Dogs
    • Cats
    • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Antimicrobial
    • Tetracyclines
    • Penicillin
    • Cephalosporins
    • Macrolides
    • Quinolones
    • Others
  • Antifungals
  • Antivirals
  • Antiparasitic
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
  • Topical
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • Prescription
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital/ Clinic Pharmacy
  • Retail Pharmacies
  • E-commerce

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Country Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Anti-infectives Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rise in Infectious Diseases Among Animals
      • 3.2.1.2. Growing Research Initiatives
      • 3.2.1.3. Increasing R&D Initiatives
      • 3.2.1.4. Development Of Novel Treatments
      • 3.2.1.5. Increasing Regulatory Approvals
      • 3.2.1.6. Growing Applications of AI
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Drop in Consumption
      • 3.2.2.2. Emerging Drug Resistance
      • 3.2.2.3. Stringent Regulations
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Anti-infectives Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework by Key Countries
    • 3.3.4. Estimated Animal Population, by Key Species, by Key Countries, 2021 - 2023
    • 3.3.5. Prevalence of Key Infectious Diseases, by key species, (2024)
    • 3.3.6. COVID-19 Impact Analysis

Chapter 4. U.S. Veterinary Anti-infectives Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Anti-infectives Market: Animal Movement Analysis
  • 4.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
  • 4.4. Livestock Animal
    • 4.4.1. Production Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Poultry
      • 4.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Swine
      • 4.4.3.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Cattle
      • 4.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Sheep & Goats
      • 4.4.5.1. Sheep & Goats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Fish
      • 4.4.6.1. Fish Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Companion Animal
    • 4.5.1. Companion Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Dogs
      • 4.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Cats
      • 4.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Veterinary Anti-infectives Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Anti-infectives Market: Product Movement Analysis
  • 5.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 5.4. Antimicrobials
    • 5.4.1. Antimicrobials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Cephalosporins
      • 5.4.2.1. Cephalosporins Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Tetracyclines
      • 5.4.3.1. Tetracyclines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Penicillin
      • 5.4.4.1. Penicillin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Macrolides
      • 5.4.5.1. Macrolides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.6. Others (Quinoles, sulfonamides, polymyxins)
      • 5.4.6.1. Others (Quinoles, sulfonamides, polymyxins) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Antifungals
    • 5.5.1. Antifungals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Antivirals
    • 5.6.1. Antivirals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Veterinary Anti-infectives Market: By Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Anti-infectives Market: By Route of Administration Movement Analysis
  • 6.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
    • 6.3.1. Oral
      • 6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Injectables
      • 6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Veterinary Anti-infectives Market: By Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Anti-infectives Market: By Type Movement Analysis
  • 7.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
    • 7.3.1. OTC
      • 7.3.1.1. OTC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Prescription
      • 7.3.2.1. Prescription Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Anti-infectives Market: By Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Veterinary Anti-infectives Market: By Distribution Channel Movement Analysis
  • 8.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
    • 8.3.1. Hospital/Clinic Pharmacy
      • 8.3.1.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Retail Pharmacies
      • 8.3.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. E-commerce
      • 8.3.3.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Zoetis
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Boehringer Ingelheim
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Merck & Co. Inc.
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Dechra Pharmaceuticals Plc.
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Elanco Animal Health
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Ceva Sante Animale
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Virbac
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Biogenesis Bago
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Vetoquinol
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Calier
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Norbrook Laboratories
      • 9.3.11.1. Participant's Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Expansion
    • 9.4.4. Product launch
    • 9.4.5. Product Approval
    • 9.4.6. Others
  • 9.5. List of Key Companies
    • 9.5.1. List of Manufacturers
    • 9.5.2. List of Distributors